©The Author(s) 2026.
World J Gastroenterol. Jan 14, 2026; 32(2): 114057
Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.114057
Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.114057
Figure 8 Cedrol treated dextran sulfate sodium-induced colitis by inhibiting inflammation, restoring the intestinal barrier, and rebalancing gut microbiota.
TNF: Tumor necrosis factor; IL: Interleukin; DSS: Dextran sulfate sodium; LPS: Lipopolysaccharide; MD2: Myeloid differentiation factor 2; TLR4: Toll-like receptor 4; MAPK: Mitogen-activated protein kinase; ERK: Extracellular regulated protein kinase; JNK: C-Jun N-terminal kinase; NF-κB: Nuclear factor kappa B; iNOS: Inducible nitric oxide synthase; COX-2: Cyclooxygenase-2.
- Citation: Zhao YQ, Zhang Y, Qin Y, Zhang RY, Wang JP. Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation. World J Gastroenterol 2026; 32(2): 114057
- URL: https://www.wjgnet.com/1007-9327/full/v32/i2/114057.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i2.114057